$CMPS is a publicly traded company in the Healthcare sector. This company operates across Healthcare and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 6 active Congressional signals mentioning $CMPS, including 6 bills. The current legislative sentiment is predominantly bullish, suggesting potential tailwinds from government policy.
S.4220 is a procedural bill establishing an administrative office within the VHA to prepare for future novel therapies including psychedelics. It authorizes zero funding and creates no near-term revenue for psychedelic drug developers. The bill remains in early committee stage. Real market data shows CMPS at $8.54 (down 10.96% in 7 days, up 54.25% in 30 days) and ATAI at $4.08 (down 12.1% in 7 days, up 14.97% in 30 days); recent price action reflects broader sector volatility, not this bill.
→ No immediate revenue from VHA for CMPS as the bill builds administrative capacity only; any future procurement depends on FDA approval of COMP360 and subsequent VHA formulary decisions.
The Freedom to Heal Act of 2025 removes a critical DEA regulatory barrier for Schedule I investigational psychedelic drugs under Right to Try laws. This directly benefits pure-play psychedelic therapy companies $CMPS, $GHRS, and $ATAI by enabling early patient access, revenue generation, and real-world data collection before full FDA approval. The bill is early-stage but has significant tailwind from an April 2026 Executive Order targeting psychedelic therapies for mental health.
→ Enables COMPASS Pathways to supply its investigational COMP360 psilocybin therapy directly to physicians for eligible patients before full FDA approval, creating an early revenue channel and real-world data collection pathway outside clinical trials.
HR2085 proposes a 25% tax credit for translational research on neurodegenerative and psychiatric conditions, with a $1B aggregate cap in 2026. The bill is in early legislative stage (referred to Ways and Means, zero committee action). The April 18 Executive Order on psychedelic therapies provides a favorable regulatory backdrop but is separate legislation. Pure-play psychedelic/psychiatric biotechs $CMPS, $GHRS, $ATAI are structurally positioned as potential beneficiaries if the bill advances, but the probability of enactment is low at this stage.
→ Reduces after-tax cost of eligible R&D by 25% for companies that receive an allocation, lowering effective cash burn for translational programs
The Freedom to Heal Act of 2025 (HR6434) is an early-stage bill that would expand Right to Try access to Schedule I investigational psychedelic drugs by creating a new DEA registration for physicians. The bill is in committee referral stage with a companion in the Senate (S3346). A recent Executive Order (April 18, 2026) accelerating psychedelic therapies aligns with this bill's intent. Pure-play psychedelic companies — $CMPS, $GHRS, $ATAI, $MNMD — are the structural beneficiaries, though the bill authorizes no direct funding and faces a long legislative path.
→ Creates a new commercial channel for investigational psychedelic drugs outside of the clinical trial framework. Physicians can legally access and administer these drugs to eligible patients (those with life-threatening conditions who have exhausted approved treatments) without enrolling in a clinical trial. This expands potential revenue sources for companies with ongoing Schedule I investigational drug programs.
The SUPPORT for Patients and Communities Reauthorization Act (P.L. 119-44) became law on December 1, 2025, extending federal substance use disorder and mental health funding through FY2030. This creates a structural tailwind for diagnostic testing (LH, DGX) and pharmaceutical distribution (CAH) via sustained grant programs, while also providing a positive policy backdrop for psychedelic therapy developers (CMPS, MNMD). Recent market data shows diagnostic stocks declining over the past 30 days, with LH at $261.79 (-1.88% 30d) and DGX at $193.52 (-1.26% 30d), suggesting the market has not yet priced in this long-term authorization catalyst.
→ Reduced regulatory risk and shorter timeline to potential FDA approval for COMPASS Pathways' COMP360 psilocybin therapy, currently in Phase 3 trials for treatment-resistant depression and being evaluated for SUD indications.
HR2623 mandates the VA to establish five innovative therapies centers focused on advanced treatments including psychedelics. The bill is in early committee stage with 27 cosponsors and no appropriated funding yet. The tickers CMPS, GHRS, ATAI, and DRUG have rallied significantly over 30 days (17% to 52%) on the Executive Order and legislative signal, but remain well below 52-week highs.
→ Creates a federal procurement pathway for psychedelic drug development contracts and clinical trial services targeting PTSD and depression in the veteran population (the single largest eligible cohort for such treatments).